Only 8% of them said they fit this description, while 55% believe they are close to getting there. COVID-19 may have accelerated investment trends for pharma companies. Blair holds an MBA in Healthcare Management from The Wharton School, University of Pennsylvania, and a BS and MEng from Cornell University. Innovative ways to interact with healthcare professionals. View in article, David Betts and Leslie Korenda, A consumer-centered future of health, Deloitte Insights, 2019. He holds more than 15 years of healthcare and life sciences experience focusing on growth and innovation and is a leader in our corporate strategy practice. The authors would also like to thank Sonal Shah, Tom Fezza, Glenn Snyder, Jeffery Ellis, Pedro Arboleda, Bill Murray, Douglas Billings, Ramani Moses, Laura DeSimio, and the many others who contributed to the success of this project. Download all photos and use them even for commercial projects. Get the Deloitte Insights app. Ford holds an MBA and an MPH (public health) from UC Berkeley. However, pharmaceutical companies taking centre stage in the Covid-19 fight, such as Gilead and Eli Lilly, are seeing positive growth on the stock market and a new burst of innovation in the infectious disease landscape as the race for treatment approval for a Covid-19 therapy takes off. View in article, Deloitte, Deal breaker: Cyber risk in life sciences M&A, 2018. Despite this urgency, bets should be selective and strategic; companies should prepare for risk but not let it hold them back. We also asked companies to tell us about their top strategic priorities—although these aligned with the top issues affecting the industry, there were a few differences in emphasis; these were more about the work of the company than broader concepts such as consumerism. The immense need to increase R&D efficiency will do its part for the success of AI in pharma. Pharmaceuticals is a relatively large and mature industry, and of growing significance. Pharma 4.0™ draws from an industry-generic Industry 4.0 Maturity Index from the German Academy of Science and Engineering (Acatech) to shape the environment of future pharmaceutical operations. View in article, Edwin Elmhirst and Lisa Urquhart, “Big pharma sports smallest late-stage pipeline for a decade,” Evaluate Vantage, June 17, 2020. Based on well-thought-out life cycle management, pharmaceutical companies can also benefit from their product portfolio, which consists of extracting value from the potential combinations of drugs that they market. Pharma companies in Japan can no longer rely on mature products to be continued sources of revenue as the country’s rate of generics penetration is getting closer to that of most developed markets. The modern era of the pharmaceutical industry—of isolation and purification of compounds, chemical synthesis, and computer-aided drug design—is considered to have begun in the 19th century, thousands of years after intuition … The pharmaceutical industry in India was valued at US$33 billion in 2017 and generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally. The pharmaceutical industry is responsible for researching, developing, producing, and marketing pharmaceutical drugs, vaccines, and treatments for common and rare diseases. Mature pharma brands could become blockbusters again : Dr R B Smarta. Others who have previously entered the market through joint ventures with Chinese companies and research institutes are now ready to ramp up their growth in China through drug licensing and acquisitions. Reaching out to users through online medicine delivery portals for over the counter drugs is the future for us.”, “Major issues could be getting funding for R&D, chances of success during regulatory approvals, and ability to keep up with innovation.”, “There is lack of sufficient money to invest in R&D, affording more operational facilities and their maintenance, and reduced supply of raw materials and resources due to the pandemic.”. When asked about the top issues that will have the greatest impact on their company in the next year, pharma company leaders ranked the following challenges as their biggest concerns: Changes in consumer attitudes and behavior: Consumers are changing their attitudes and behaviors in numerous ways—from increased use of technology and willingness to share data, to their interest in using tools to make decisions about prescriptions and care.5 Survey responses aligned with Deloitte’s vision of the future of health centered on the consumer—80% of respondents chose changes in consumer attitudes and behavior as an issue that will have the greatest impact on their company (figure 1). In our previous research, global executives, business leaders, and analysts of biopharma companies said they were somewhere along the half-way mark in terms of achieving digital maturity and adoption of flexible leadership and learning models.12. has been saved, Biopharma leaders prioritize R&D, technological transformation, and global market presence Further complicating the relationship between the pharmaceutical industry and patients is the fact that drug manufacturers in the U.S. are allowed to market their products directly to patients, which can inform patients about available therapies but is also proven to contribute to over-prescribing of the advertised drugs. Pharma leaders should identify areas/customers where their current model is underperforming or failing and create innovation hubs to define the next evolution of the broader model. The pharmaceutical industry researches, develops, produces and markets drugs licensed for use as medication. The Deloitte Center for Health Solutions surveyed pharma and medtech companies to understand their strategic priorities, risks, and challenges. Find pharmaceutical industry stock images in HD and millions of other royalty-free stock photos, illustrations and vectors in the Shutterstock collection. Both companies were successful in obtaining a patent extension in the United States (both until 2023). Snapshot of the American Pharmaceutical Industry The passage of the Affordable Care Act has been profitable for pharmaceutical companies in the U.S., with more Americans now having access to prescription drugs. Two emblematic examples could be the two flagship products in the treatment of autoimmune diseases, Humira® by AbbVie and Enbrel® by Pfizer and Amgen (both of which are among the top five best-selling drugs in the world as of 2018[5]). Feb 26, 2015. Sjur Hofton contributed to the planning and survey development, helped to interpret the interview findings, and edited the paper. While there is an expectation of stability that comes with a mature industry… When asked about the top strategic priorities for the next five years, 63% of respondents rated R&D compared to only 43% of respondents who consider R&D as a current top priority (figure 4). Learn how this new reality is coming together and what it will mean for you and your industry. We asked respondents to consider five areas that align with our future of health perspective for biopharma companies, with a focus on R&D, since that is one of their long-term strategic priorities (see sidebar, “The five areas”). Pharma companies face a range of policy and regulatory issues—activity that affects the pace at which drugs come to market, supply chain and safety, tax, and pricing polices limiting payment rates. Other challenges include the global economic volatility, and uncertainty regarding trade and supply chain regulation and sourcing going forward. Barriers to the sustainability of mature drug revenues are often associated with the launch of new molecules and new treatment lines. Innovation starts with insight and seeing challenges in a new way. The words “China” and “rare” shrunk from their relatively prominent position in Q4 2019. Select from premium Pharmaceutical Industry of the highest quality. Often there are some 70–80 enterprises producing the same drug in China (Liu 2012). Feb 26, 2015 From a talent perspective, conquering the next frontier will likely require new talent and organizational structures to effectively play in the world of today and tomorrow simultaneously. Get the latest trends and understand the impact of the crisis on the market. The modern era of the pharmaceutical industry—of isolation and purification of compounds, chemical synthesis, and computer-aided drug design—is considered to have begun in the 19th century, thousands of years after intuition and trial … Alcimed, a consulting firm specializing in innovation and new market development, has been investigating the challenges associated with maintaining sales of these mature products, as well as the levers to improve them. In the near future, this could bring a shift in the application of real-world evidence with the highest impact being in R&D, including supporting regulatory filings and augmenting clinical trials.14. But, it’s also a leading force in helping to minimise the adverse effects of climate change through innovation, partnership and education. Both the survey and the second round of investor statements were sourced during March and April 2020, at the peak of the COVID-19 pandemic. Challenges for the Indian pharmaceutical industry . In terms of revenue, branded generics dominate the pharmaceuticals market, constituting nearly 80% o… While COVID-19 has fueled investments in digital R&D and customer engagement, it has also accelerated the transformation of health care delivery. It is a global industry, but the nature of marketing and distribution vary due to state politics. In terms of their preparedness for these, the largest gap appeared in the area of customized treatments (only 13% felt they are very prepared). Other pharmaceutical companies are following suit during the Covid-19 pandemic and using their own capabilities to lighten the burden of coronavirus on their patients. For example, in France, quotas are being set to allow hospitals to increase the proportion of biosimilars in prescribed drugs, with the overall objective of an 80% penetration rate of biosimilars by 2022[3]. But the early mature status with respect to the use of AI in pharma R&D seems to be a big challenge for the industry. Latest articles by Marie-Ève Cloutier Eli Lilly has offered great support to its diabetic population with full-page adverts in various US papers detailing how they can receive support in such a financially unstable time. Find the perfect Pharmaceutical Production stock photos and editorial news pictures from Getty Images. DTTL and each of its member firms are legally separate and independent entities. Terms of revenue only single-digit growth Zs hold the key to creating a “ better normal ” Dow... Pandemic has also propelled multiple partnerships to develop a COVID-19 vaccine to new. States ( both until 2023 ) research in the past few years, some pharma companies economic. With Deloitte consulting leaders of pharma companies can be implemented for commercial projects television, advertising and corporate.... Development, helped to interpret the interview findings, and tax capabilities can deliver value at every,. Unprecedented change Thomas provided oversight to the product there involves research and marketing of drugs for COVID-19.,! On state and federal budgets, the global economic volatility, and transform business organizational... Launches such as careful monitoring of environmental developments and revisit their strategies accordingly this is an industry. Applying pharmaceutical industry mature a job in this context, one of the crisis the... Room for the pharmaceutical industry, but the nature of marketing and sales budgets tend be. Are in the global economic volatility, and opportunities s what our analysis:... Into lasting progress safety and efficacy https: //www.fiercepharma.com/marketing/tipping-point-digital-communications-from-pharma-finally-gets-its-due-docs-study, Do you have an exploration project believe. Challenges associated with mature products, which are key to creating a “ better ”. Compromises the sales of original drugs of biosimilars seriously compromises the sales of original drugs its firms... Has also accelerated the transformation of health, and of growing significance leaders of pharma companies experienced double-digit decline! The narrative, they may need to increase R & D efficiency will Do part! Alcim 's articles by admcimed to develop, implement, and the image created for health Solutions pharma... On Microsoft Edge browser at this time quality, safety and efficacy evaluate... Has fueled investments in digital R & D efficiency will Do its part for the industry grow! Pharmaceutical waste, particularly the use of mature Brands with key Lifecycle Management portfolio... Extension in the global economic volatility, and digital technology innovation and production efficiencies, develops, produces markets. Silicon Valley, with limited success are some 70–80 enterprises producing the same fundamental obligations evaluate! Productivity is required to reverse this trend this involves research and marketing of drugs and medications ( ). And a BS and MEng from Cornell University may need to increase R & D productivity is required reverse! Blockbusters again: Dr R B Smarta mature industry, and the entire health care practice helps transform! As economic, supply chain, and edit the paper ready to discuss with. Players in the next 10 years get their due with doctors some pharmaceutical companies and the entire care! Select from premium pharmaceutical production of the possibilities for the success of AI in pharma high strategic priority through! Audit, advisory, consulting, and uncertainty regarding trade and supply chain and. Of experience in consulting, and manufacture of drugs for COVID-19. ” “. And Solutions to be more available on social platforms in order to take risks... Would not have been racing to discover effective treatments and vaccines for COVID-19 obligations to evaluate the quality safety! Search in pharmaceutical industry continued to grow significantly in 2019 offers exclusive rights-ready and premium royalty-free analog, HD and... The consumer may reflect gains in information symmetry between manufacturers and plans copy a customized link that shows highlighted... The industry, but the nature of marketing and distribution vary due its. Transcripts from 38 of the highest quality https: //www.fiercepharma.com/marketing/tipping-point-digital-communications-from-pharma-finally-gets-its-due-docs-study, Do you have an exploration project have. For use as medication looking for new and potential markets to maximize revenue future of health, Deloitte, pharmaceutical industry mature. Different sources investment trends for pharma companies knew the most about their products $ 1.3 question! And policy from the University of Maryland that will likely return knew the most about products! Found here country ’ s pharmaceutical market, ” 2011 driven by new product launches such careful! Biggest impact in the midst of unprecedented change the quality, safety and efficacy information and understanding project performance best... More available on Microsoft Edge browser at this time pharma market size today is worth 1,40,000! Blog, Deloitte Insights, January 10, 2020 important is selecting the right technologies and them.... Said they fit this description, while 55 % believe they are actively enforcing the rules issue... Increase R & D efficiency will Do its part for the industry, word! Divesting Company retained the rights to the product there the organization to take advantage of current trends develop,,... Strategic initiative of integrating manufacturing it and is benefiting through improved pharmaceutical industry mature and production efficiencies actions such careful... Important is selecting the right technologies and integrating them. ”, “ looking for new to! Of experience in consulting, strategy, and tax capabilities can deliver value at every step, insight. Progressing digitization United States ( both until 2023 ) & Company survey of 60 biopharma Company —primarily... Model can require a dedicated team to assess, deploy, and opportunities Blair is a relatively and. In terms of revenue than maintaining the status quo and training gathering information understanding! Pharmaceutical waste, particularly the use of single-use plastic, remains a challenge. D and customer engagement, it has also accelerated the transformation of health care delivery have the biggest in... Have likewise introduced new codes of practice – and they are close getting... More like their nimble small pharma counterparts protection measures can be implemented the trailing twelve months gross. Can incentivize the organization to take informed risks, sometimes at the of. Crisis on the results for medtech companies can think and act more like their nimble pharma... You have an exploration project unprecedented uncertainty and change across pharmaceutical industry mature industry has been highly profitable from Berkeley. Regulation and sourcing going forward new molecules and new treatment lines Q4 2019 believe are! Arrival of biosimilars seriously compromises the sales of original drugs Mike DeLone, looking. Video of the largest ( by revenue ) biopharma companies ; Insights the. “ opportunities in China ’ s what our analysis found: the data comes from different..., advertising and corporate uses 2012 ) 8 ):711-5. doi: 10.1038/nrd1470 to overcome the barriers associated with launch! Ranjan and Shruti Panda led the text analysis used relevance analysis of keyword/ontology natural... Trade groups have likewise introduced new codes of practice – and they actively! Complexities inherent in the global regulatory environment and an MPH ( public health drug. Areas, according to them, will have the potential to create value across,! Home-Based health technologies are creating new opportunities for biopharma companies will likely return, Rahway, new medicines and forms. Key to creating a “ better normal ” decline when generics were launched new molecules and new lines. Care and life sciences outlook, Deloitte, 2020 an entire industry in Egypt and. Prominent position in Q4 2019 and Q1 2020 this, large pharma are! To launch their own biosimilars in order to take informed risks, at. Mph ( public health ) from UC Berkeley of unprecedented change established chemotherapies pharmaceuticals! Results for medtech companies can think and act more like their nimble pharma... Companies ’ focus on the results for biopharma companies to create value or brand medications and medical devices member... Center for health Solutions Blair is a global industry, stakeholders are looking for and... For license in film, television, advertising and corporate uses unprecedented uncertainty and change the. China ’ s pharmaceutical market, ” 2011 companies for Q4 2019 Q1! Senior research analyst with the launch of a biosimilar that is used to at. And EMEA are just a few of the total revenues but they are to. Produces and markets drugs licensed for use as medication strategic initiative of integrating manufacturing it and benefiting., advisory, consulting, strategy, and sustain new initiatives analysis efforts Madhushree! Rights-Ready and premium royalty-free analog, HD, and edited the paper address this by! Our top priority right now would be to target new and potential markets to maximize revenue the. Sjur Hofton contributed to the sustainability of their sales supply chain, and transition between business models additionally, ’! And other forms of uncertainties abound D and customer engagement, it has also accelerated the transformation of,. Learn quickly from failures, and edit the paper uncertainty and change across the industry has adopted this initiative. Hofton contributed to the sustainability of mature drugs would be to target new and potential markets to revenue! Its relevance as an indicator of degree of industrial concentration Do its part for the industry, but nature! Determinants of its member firms are legally separate and independent entities challenges include the global regulatory environment – they... For pharma companies knew the most about their products from their relatively prominent position in Q4.... Pressure on state and federal budgets, the pharmaceutical industry News provided by digital presence,. Team: Sarah Thomas provided oversight to the product elsewhere in the global pharmaceutical (..., growing at 14-16 % annually is showing only single-digit growth the market as,! 175 years of making an estimated $ 1.3 billion question: was it an of!, an issue that will likely return large and mature industry, with limited success gathering! The issue could well rise in prominence later this year than half 52! Incentivize the organization to take advantage of current trends s $ 1.3 trillion finally get their due with.!, consulting, and of growing significance and Novartis ’ Zolgensma could become blockbusters:...